TB-500: A Synthetic Thymosin Beta-4 Fragment for Tissue Repair Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to TB-500. TB-500 is not FDA-approved for human use and, as of April 2026, is classified as an FDA 503A Category 2 bulk drug substance, meaning it is prohibited for use in compounding by licensed pharmacies. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Every major joint injury carries the same hope: that somewhere, something exists that accelerates the biology of repair faster than rest and physical therapy alone. TB-500 has become one of the most discussed peptide candidates for that role in athletic and wellness communities. The conversation usually conflates two things that are meaningfully different: TB-500 as sold by research vendors (a synthetic 17-amino acid fragment) and thymosin beta-4 (the full 43-amino acid native protein it is derived from). Those are not the same compound, and almost all of the clinical data cited in support of TB-500 was generated using the full-length molecule.

Here is what TB-500 actually is, what the evidence shows at each level of the research hierarchy, what regulators have done about it, and what an accurate picture of this compound looks like in 2026.

Key Takeaways

• Regulatory Status: Not FDA-approved for human use. As of the February 2026 reclassification, TB-500 (as a thymosin beta-4 fragment) is classified as an FDA 503A Category 2 bulk drug substance, prohibited in compounding. Full-length thymosin beta-4 (Tβ4) has progressed through clinical trials under a separate regulatory track for an ophthalmic indication, but TB-500 specifically has not.
• Research Stage: Preclinical only for musculoskeletal and tissue-repair indications. No completed human efficacy trials for TB-500 (the 17-amino acid fragment) have been published as of April 2026. Clinical data involving full-length Tβ4 exists but does not transfer directly to TB-500.
• Availability: TB-500 cannot be legally obtained through a licensed compounding pharmacy in the United States. Superpower Health does not prescribe, sell, or facilitate access to TB-500.
• Prescribing information: View compound reference data (PubChem CID 16133418)
• What it is: A synthetic N-terminal-acetylated 17-amino acid fragment of thymosin beta-4 (sequence: Ac-LKKTETQ-OH), covering the actin-binding domain of the parent protein.
• What the evidence actually shows: Animal wound-healing data using both full-length Tβ4 and short actin-binding fragments exists. As of April 2026, no completed, published human RCTs have examined TB-500 (the 17-AA fragment) for any musculoskeletal or tissue-repair indication.

Where TB-500 Comes From and How It Differs from Thymosin Beta-4

Origin and chemical identity

Thymosin beta-4 (Tβ4) is a 43-amino acid protein found throughout human tissue. It was originally isolated from thymic tissue and has been studied for decades as a regulator of actin polymerization. As Goldstein, Hannappel, and Kleinman described in a 2005 review published in Trends in Molecular Medicine, Tβ4 is an actin-sequestering protein that also operates in repair contexts beyond simple cytoskeletal maintenance, including dermal wound healing, corneal repair, and post-ischemic cardiac signaling. A subsequent 2012 review by Goldstein, Hannappel, Sosne, and Kleinman in Expert Opinion on Biological Therapy expanded this picture across dermal ulcer, corneal, and cardiac applications. The structure–function basis was mapped by Crockford, Turjman, Allan, and Angel in a 2010 review in the Annals of the New York Academy of Sciences, which identified the actin-binding motif at residues 17–23 (LKKTETQ) as the functional core — the biochemical basis on which TB-500 was later designed. TB-500 is not this molecule. TB-500 is the synthetic N-terminal-acetylated fragment corresponding to residues 17 through 23 of Tβ4 (Ac-LKKTETQ-OH), first characterized for analytical purposes by Esposito, Deventer, Goeman, Van der Eycken, and Van Eenoo in a 2012 study published in Drug Testing & Analysis. That paper was commissioned not for therapeutic development, but because TB-500 was already circulating in equine doping contexts and required a detection method. The fragment covers the actin-binding domain of the parent protein. It is a laboratory-synthesized compound with no naturally occurring isolated form in human biology.

Why the fragment design was proposed

The rationale for studying a short fragment rather than the full protein traces to a 2003 paper by Philp and colleagues published in Wound Repair and Regeneration. That study showed that both full-length Tβ4 and a synthetic peptide containing only its actin-binding domain accelerated dermal wound healing in diabetic and aged mouse models. This was the mechanistic evidence suggesting that the actin-binding sequence (residues 17 to 23) might retain biologically relevant activity independently of the full protein. The short-fragment approach appealed to researchers because synthetic small peptides are generally easier to manufacture, characterize, and study than full-length proteins. However, as Sosne, Qiu, Goldstein, and Wheater demonstrated in a 2010 paper in FASEB Journal, Tβ4's biological activities map to multiple distinct short peptide sequences, including both the actin-binding region and a separate C-terminal AGES domain. TB-500 covers only one of those domains.

The actin-sequestration mechanism

The core proposed mechanism for both Tβ4 and TB-500 involves actin dynamics. In resting cells, Tβ4 binds G-actin (globular actin monomers) and prevents their incorporation into F-actin (filamentous actin), effectively buffering the pool of available actin for rapid cytoskeletal reorganization. When a cell receives a migration or repair signal, this buffered actin is released and incorporated into lamellipodia and other structures that enable cell movement. A 1997 study by Malinda, Goldstein, and Kleinman in FASEB Journal established that Tβ4 stimulates directed migration of human umbilical vein endothelial cells via this mechanism. That finding grounded all subsequent work on Tβ4 and angiogenesis. The actin-binding domain was subsequently shown by Philp and colleagues in a 2003 paper in FASEB Journal to drive this angiogenic effect, which is the mechanistic basis for the argument that the TB-500 fragment retains pro-angiogenic activity. The relevance of this mechanism to human tissue repair remains under investigation; it has not been confirmed in a controlled human study of the 17-AA fragment.

What the Animal Research Shows, and What It Cannot Confirm

Preclinical tissue-repair findings

The preclinical literature on Tβ4's tissue-repair effects is substantial, spanning dermal wound healing, corneal repair, cardiac ischemia, and neurological injury. Philp and Kleinman reviewed this body of work in a 2010 paper in the Annals of the New York Academy of Sciences, concluding that animal models consistently show accelerated healing across multiple tissue types when full-length Tβ4 is administered. A landmark 2004 study by Bock-Marquette and colleagues published in Nature demonstrated that intracardiac Tβ4 activates integrin-linked kinase, promotes cardiomyocyte migration and survival, and improves cardiac function after experimental myocardial infarction in mice. A 2007 follow-up by Smart and colleagues, also in Nature, showed that Tβ4 mobilizes adult epicardial progenitor cells and induces neovascularization of the injured heart. A 2007 synthesis review by Srivastava, Saxena, DiMaio, and Bock-Marquette in the Annals of the New York Academy of Sciences summarized the cardioprotective picture across these studies. These are compelling animal findings. They were also produced using full-length Tβ4, not the 17-AA TB-500 fragment.

The cardiac data gap specific to TB-500

An important piece of counter-nuance appears in a 2015 paper by Hinkel and colleagues published in the Journal of Molecular and Cellular Cardiology. That study identified the C-terminal AGES domain of Tβ4 as the primary driver of post-ischemic cardiac benefit. TB-500 covers the N-terminal actin-binding region (residues 17 to 23), not the AGES domain. This means the cardiac-repair biology that produced the strongest Tβ4 animal findings may not transfer to the TB-500 fragment at all. A 2018 large-animal pig study by Ziegler, Bähr, and colleagues published in Molecular Therapy confirmed neovascularization and cardiac function improvements with Tβ4 gene therapy in chronic myocardial ischemia, again using the full-length molecule, not the fragment. The cardiac data, compelling as it is, belongs to Tβ4, not to TB-500.

Absence of human RCT data for musculoskeletal indications

A 2025 review by DeFoor and Dekker published in Arthroscopy specifically examined injectable therapeutic peptides, including TB-500 and BPC-157, in the context of regenerative medicine and sports performance, noting that the orthopaedic literature investigating clinical use and outcomes of such peptides remains scarce and that human randomized controlled trial data for TB-500 in musculoskeletal indications does not exist. The claim that TB-500 accelerates tendon, ligament, or muscle healing in humans is an extrapolation from Tβ4 animal work and the mechanistic argument that the actin-binding fragment retains relevant activity. That argument is plausible but untested in humans. Any consumer-facing claim that TB-500 "heals" or "repairs" specific tissues in people outruns the published evidence by a substantial margin.

What the Human Evidence Actually Shows (Tβ4, Not TB-500)

Corneal wound healing: the strongest signal in the Tβ4 literature

The most rigorous human data for any Tβ4-derived therapy comes from the ophthalmic program developed by RegeneRx under the designation RGN-259. The preclinical foundation was established by Sosne and colleagues in a 2002 Experimental Eye Research paper showing that Tβ4 promotes corneal wound healing and reduces inflammation after alkali injury. A 2010 case report series by Dunn and colleagues in the Archives of Ophthalmology then documented an early human signal, with topical Tβ4 ophthalmic solution healing chronic nonhealing neurotrophic corneal epithelial defects in a small uncontrolled patient series (no placebo comparator; uncontrolled case-series design limits the strength of this signal). Sosne, Dunn, and Kim reported a Phase 2 double-masked placebo-controlled RCT in a 2015 paper in Cornea in which 9 patients with severe dry eye (18 eyes) received RGN-259 (0.1% Tβ4) eye drops six times daily versus vehicle for 28 days; at day 56 the treatment arm showed a 35.1% reduction in ocular discomfort by OSDI score (p = 0.0141) and a 59.1% reduction in total corneal fluorescein staining (p = 0.0108), with no treatment-related adverse events reported. The very small cohort is a clear limitation of this early-phase signal. A later Phase 3 RCT reported by Sosne, Kleinman, Springs, and colleagues in a 2022 paper in the International Journal of Molecular Sciences examined 0.1% RGN-259 (full-length Tβ4) ophthalmic solution in 18 patients (10 treatment vs 8 placebo) with Stage 2–3 neurotrophic keratopathy in a double-masked, placebo-controlled design; the 4-week complete-healing primary endpoint trended positively but did not reach conventional significance (60% vs 12.5%, p = 0.0656), while healing at day 43 was significant (p = 0.0359) and disease-stage improvement reached p = 0.0467, with no significant adverse effects reported. The N of 18 is small for a Phase 3, and the primary endpoint missed the p < 0.05 threshold — both limitations to weigh when interpreting the trial. A 2018 "bench to bedside" review by Sosne in Expert Opinion on Biological Therapy traces the full ocular development narrative from preclinical models through Phase 2 and 3. This is the highest-quality human evidence in the entire Tβ4 literature. It involves the full-length 43-amino acid molecule administered as an eye drop, not an injectable fragment. It does not validate TB-500 for systemic tissue repair, and any attempt to cite this trial in support of injectable TB-500 use misrepresents the research.

Dermal and venous ulcer data

A 2007 European multicenter double-blind placebo-controlled dose-escalation Phase 2 RCT by Guarnera, De Rosa, and Camerini published in the Annals of the New York Academy of Sciences randomized patients with chronic venous ulcers 3:1 to topical full-length Tβ4 versus placebo alongside standard compression therapy for 84 days (with 14-day follow-up); at the time of publication 21 patients had been enrolled in the first dose cohort, with primary endpoints of complete ulcer closure at day 84 and mean time to healing assessed via digital planimetry. The abstract reports acceptable safety and tolerability across clinical chemistry, hematology, coagulation, and urinalysis monitoring but does not report definitive efficacy effect sizes, reflecting the preliminary dose-escalation design and the small enrolled cohort. The small per-arm sample and topical wound-context delivery both limit extrapolation to systemic TB-500 use. A 2012 review by Treadwell and colleagues, also in the Annals of the New York Academy of Sciences, synthesized preclinical and patient data on dermal healing with Tβ4, including work in pressure ulcers and epidermolysis bullosa. These studies involve topically or locally administered full-length Tβ4 in specific wound contexts. They represent the human safety and tolerability signal for the Tβ4 class, but they do not constitute efficacy evidence for the TB-500 fragment in musculoskeletal applications.

What this means for interpreting TB-500 claims

The summary picture is this: full-length Tβ4 has navigated Phase 2 and Phase 3 human trials in corneal applications. It has human safety data from venous ulcer studies. It does not have approved status for any systemic indication. TB-500 (the 17-AA fragment) has none of this: no completed human efficacy trials, no published human pharmacokinetic data, and no independent confirmation that the fragment produces the same downstream biology as the parent protein in human tissue. The 2025 orthopaedic review by DeFoor and Dekker in Arthroscopy confirmed this gap is not a matter of missing literature. It is the current state of the science.

Regulatory and Legal Status

FDA classification

As of April 2026, TB-500 is classified as an FDA 503A Category 2 bulk drug substance following the February 2026 reclassification. This means it is prohibited for use in compounded medications under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It is not FDA-approved for any human therapeutic indication. Full-length thymosin beta-4 (Tβ4) occupies a separate regulatory track, having entered human clinical trials under an IND, but the ophthalmic RGN-259 program has not resulted in FDA approval for any indication as of April 2026.

WADA prohibition and the equine doping context

For athletes, there is a separate regulatory consideration. As of the 2026 WADA Prohibited List, TB-500 is prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The S2 category covers thymosin beta-4 and its fragments. The prohibition reflects the presumption of tissue-repair benefit, not a demonstrated performance effect. A 2019 systematic review by Heuberger and Cohen in Sports Medicine noted that many WADA-listed substances lack clear performance-enhancing evidence; TB-500's S2 inclusion is based on proposed mechanism rather than sport-specific RCT data.

TB-500's equine doping history is not incidental. The 2012 LC-MS detection method published by Ho, Kwok, Lau, and colleagues in the Journal of Chromatography A was developed specifically because TB-500 misuse in racehorses required routine testing capacity. A 2024 population study by Delcourt and colleagues in Drug Testing & Analysis confirmed continued horse-racing use and described a global anti-doping response to Tβ4 and its fragments. This context matters: TB-500 entered human wellness circles from a veterinary doping background, not from a clinical development program.

What this means practically

TB-500 cannot be obtained through a licensed compounding pharmacy in the United States. Products marketed as TB-500 for human use exist in unregulated research chemical channels with no quality control, no sterility assurance, no verified purity, and no dosing validation. The FDA Category 2 classification reflects the agency's assessment that the compound does not meet the standards required for inclusion in compounded medications. Athletes subject to WADA testing who use TB-500 in any form face the risk of a positive anti-doping result under the S2 category.

TB-500 vs. BPC-157: Key Differences

TB-500 and BPC-157 are frequently discussed together in wellness and athletic communities as a combined investigational approach. This comparison is for scientific context only. These compounds have fundamentally different origins, mechanisms, and regulatory histories, and there are no FDA-approved or clinically validated protocols for combining them.

BPC-157 is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence of a human gastric juice protein. TB-500 is derived from the actin-binding domain of thymosin beta-4, a native 43-amino acid protein with a distinct tissue distribution and biology. BPC-157's proposed mechanisms center on nitric oxide pathways, VEGFR2-Akt-eNOS signaling, and FAK-paxillin-mediated fibroblast migration. TB-500's proposed mechanism centers on actin sequestration, cell motility, and angiogenesis through the actin-binding domain. Both are classified as FDA 503A Category 2 bulk drug substances as of 2026, and both appear on the WADA Prohibited List. Neither has completed human efficacy trials for musculoskeletal applications. The practical difference for research evaluation purposes is that the Tβ4 parent molecule has reached Phase 3 human trials in ophthalmology, giving Tβ4 a richer human data context than BPC-157's parent protein, which has no comparable clinical program.

Safety: What Is and Is Not Known

Absence of clinical safety data for the fragment

There are no published Phase 1 or Phase 2 human safety studies specifically examining the 17-AA TB-500 fragment. Human safety and tolerability data exists for full-length Tβ4 in ocular and wound-healing contexts, as described above. Whether the TB-500 fragment produces the same safety profile as the parent protein in systemic administration cannot be determined from existing literature. The pharmacokinetics of the fragment in humans (half-life, bioavailability, and tissue distribution) have not been published.

Risks from unregulated sources

Products sold as TB-500 through research chemical vendors are manufactured without pharmaceutical oversight. Independent testing of peptide products in this market has documented contamination with unintended compounds, inaccurate dosing, degraded peptide chains, and misidentified substances. There is no legal pathway to pharmaceutical-grade TB-500 for human use in the United States. The administration of any injectable compound from unregulated sources carries infection risk independent of the compound's proposed mechanism.

Who Should Not Use TB-500

Based on TB-500's proposed mechanisms, the following populations face elevated theoretical risk. This is not a complete safety assessment; it reflects the mechanistic concerns that would apply if the compound's proposed effects do operate in humans:

• Individuals with active or suspected cancer: TB-500's proposed pro-angiogenic mechanism could theoretically support tumor vascularization, consistent with the general concern for angiogenic agents in oncology contexts.
• Pregnant or breastfeeding individuals: No safety data exists for these populations. Thymosin beta-4 plays roles in embryonic development, making the fragment's effects in pregnancy unpredictable.
• Competitive athletes: TB-500 is prohibited at all times under WADA S2 as of the 2026 Prohibited List. Use in any form risks a positive anti-doping result with associated sporting consequences.
• Individuals with cardiovascular conditions: Given Tβ4's proposed cardiac and vascular signaling activities, use of the fragment in individuals with active cardiovascular disease represents an unstudied risk.
• Individuals taking anticoagulants or with coagulation disorders: Pro-angiogenic compounds may interact with coagulation pathways; no human data characterizes this interaction for TB-500.

Which Biomarkers Are Relevant if You Are Exploring Peptide Science?

If the underlying concern driving interest in TB-500 is tissue repair, recovery, or inflammation, those biological processes are objectively measurable. Establishing a biomarker baseline creates a reference point for any clinical conversation. In the case of someone already using an investigational compound, that baseline provides the only objective data for evaluating what is actually changing in their biology.

• High-sensitivity C-reactive protein (hs-CRP): The primary blood marker for systemic inflammation. TB-500's proposed mechanism includes anti-inflammatory activity; hs-CRP levels provide a quantifiable baseline and follow-up reference point for anyone monitoring inflammatory status in the context of injury or recovery.
• Complete blood count (CBC): Baseline white cell counts, hemoglobin, hematocrit, and platelet counts assess immune function and hematological status. For any investigational compound with proposed effects on angiogenesis and tissue vascularity, CBC establishes the pre-exposure hematological picture.
• Liver function panel (ALT, AST, GGT): Any investigational compound administered by injection carries baseline hepatic monitoring rationale. Liver function markers establish whether hepatic status is normal before and during use of any uncharacterized compound.
• IGF-1: Some peptide compounds proposed for tissue repair are claimed to interact with growth factor pathways. IGF-1 baseline and response data provides relevant context, particularly for individuals evaluating multiple investigational compounds. IGF-1 is available as part of Superpower's strength and resilience biomarker panel.
• Markers of systemic inflammation and recovery: For individuals dealing with overtraining, injury, or slow recovery (the contexts most commonly associated with TB-500 interest), a broader look at inflammation and muscle recovery biomarkers including CRP, CBC differentials, and metabolic markers gives a fuller picture than any single test.
• Kidney function (creatinine, BUN, eGFR): Baseline renal function is a standard monitoring marker for any investigational injectable compound, given that renal clearance pathways are often involved in peptide elimination.

When to Take This Seriously

Persistent joint pain, tendon dysfunction, slow recovery from injury, and chronic musculoskeletal problems are real clinical presentations with established evaluation pathways. A sports medicine physician, orthopedic specialist, or primary care provider can assess these conditions, order relevant imaging, and discuss evidence-based interventions. The absence of human efficacy data for TB-500 does not mean nothing works for these presentations. It means the compound has not established itself as a demonstrated option within the clinical evidence framework. Understanding your joint health and injury-related biomarkers gives any clinical conversation an objective data foundation. That foundation matters more, not less, when evaluating compounds with limited human evidence.

That commitment to data before decisions is what drives Superpower's approach to preventive health: the belief that understanding your biology is the foundation for every health decision, whether you are evaluating established therapies or following the frontier of emerging peptide research.

IMPORTANT SAFETY INFORMATION

TB-500 is not FDA-approved for any indication. As of April 2026, it is classified as an FDA 503A Category 2 bulk drug substance, prohibited for use in compounded medications by licensed pharmacies in the United States. Superpower Health does not prescribe, sell, compound, or facilitate access to TB-500. This educational content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

No completed human efficacy trials for TB-500 (the 17-amino acid synthetic fragment) have been published as of April 2026. Claims regarding tissue repair, tendon healing, or musculoskeletal recovery in humans have not been substantiated by controlled clinical data specific to this compound. Human safety and tolerability data for the 17-AA fragment specifically has not been published.

Risks associated with unregulated peptide products: Products marketed as TB-500 through research chemical vendors operate outside pharmaceutical manufacturing oversight. Such products carry risks including microbial contamination, inaccurate dosing, degraded peptide content, and misidentified compounds. Injectable administration of any unregulated compound carries additional risk of injection-site infection and systemic infectious complications.

Sport prohibition: As of the 2026 WADA Prohibited List, TB-500 is prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to WADA-compliant testing who use TB-500 in any form risk a positive anti-doping result.

Populations with elevated theoretical risk based on proposed mechanisms: individuals with active or suspected malignancy (proposed pro-angiogenic mechanism); pregnant or breastfeeding individuals (no safety data; Tβ4 has known roles in embryonic development); individuals with active cardiovascular conditions; individuals taking anticoagulant medications.

Long-term safety data: Long-term safety data for the TB-500 fragment in humans does not exist. Any use represents exposure to an incompletely characterized compound.

Compound reference data: PubChem CID 16133418.

Additional Questions

Does TB-500 show up on a drug test?

Yes. TB-500 and thymosin beta-4 fragments are detectable in biological samples. Detection methods for TB-500 in equine urine and plasma were published by Ho and colleagues in the Journal of Chromatography A in 2012, and a 2024 population study by Delcourt and colleagues in Drug Testing & Analysis described current anti-doping surveillance strategies. Human anti-doping testing for WADA-prohibited peptides follows comparable analytical approaches.

Are there any human studies on TB-500?

No completed, peer-reviewed human efficacy trials for TB-500 (the 17-amino acid synthetic fragment) have been published as of April 2026. Human clinical trial data exists for full-length thymosin beta-4 in ophthalmic indications, including a Phase 3 RCT in neurotrophic keratopathy reported by Sosne, Kleinman, Springs, and colleagues in 2022 in the International Journal of Molecular Sciences (N = 18; primary 4-week healing endpoint 60% vs 12.5%, p = 0.0656). That data applies to the full-length molecule administered topically to the eye, not to systemically administered TB-500.

Are peptides legal again after 2026?

The regulatory landscape for peptides has evolved through multiple FDA rulemaking cycles. As of April 2026, TB-500 remains classified as a Category 2 bulk drug substance, prohibited in compounding. Some other peptides have different classification statuses depending on their individual regulatory histories. The February 2026 reclassification confirmed TB-500's prohibited status rather than reversing it. For authoritative current information, consult the FDA's published bulk drug substances list.